Repurchase of Elekta shares

Repurchase of Elekta shares

The Board of Directors of Elekta AB (publ) has decided to utilize the
authorization received from the Annual General Meeting to repurchase
shares in the company.

Elekta's new distribution policy is to distribute 30 percent or more of
net profit to shareholders in the form of dividends, share repurchases
or comparable measures.

Elekta's Annual General Meeting on September 15, 2009 resolved to
authorize the Board to decide on the acquisition of a maximum of 10
percent of the total number of shares in the company.

The Board has today decided to exercise the mandate by authorizing the
executive management to initiate, on appropriate occasion, the
repurchase of shares in an amount of MSEK 100 and not more than 650,000
shares, corresponding to 0.7 percent of the total number of outstanding
shares in the company.

The purpose of the repurchase of own shares is firstly to align the
Company's capital structure to the Company's capital requirements and
where appropriate to be able to transfer shares in conjunction with the
financing of company acquisitions and other types of strategic
investments and acquisitions. In addition, the purpose is to facilitate
hedging of costs and delivery in relation to the Performance Share
Program 2009.

The total number of shares in Elekta as of June 8, 2010 was 92,795,244
shares and Elekta currently does not hold any shares in the Company.

Purchases will be made on NASDAQ OMX Stockholm and at a price within the
spread at the time of the purchase. Purchases can be made during the
time until next Annual General Meeting.

For further information, please contact:

Stina Thorman, Vice President Corporate Communications, Elekta AB
Tel: +46 8 587 254 37, email:
stina.thorman@elekta.com (stina.thorman@elekta.com)
Time zone: CET: Central European

 About Elekta

Elekta is a human care company pioneering significant innovations and
clinical solutions for treating cancer and brain disorders. The company
develops sophisticated, state-of-the-art tools and treatment planning
systems for radiation therapy and radiosurgery, as well as workflow
enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing
intelligent and resource-efficient solutions that offer confidence to
both healthcare providers and patients, Elekta aims to improve, prolong
and even save patient lives, making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over
5,000 hospitals globally, and every day more than 100,000 patients
receive diagnosis, treatment or follow-up with the help of a solution
from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate
headquarter is located in Stockholm, Sweden, and the company is listed
on the Nordic Exchange under the ticker EKTAb.